{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:41:55Z","timestamp":1791243715628,"version":"4.1.0"},"reference-count":205,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.critrevonc.2012.12.009","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T18:18:06Z","timestamp":1359569886000},"page":"146-171","source":"Crossref","is-referenced-by-count":362,"title":["Diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"87","author":[{"given":"Maurizio","family":"Martelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Agostinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.critrevonc.2012.12.009_bib0005","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1207843","article-title":"The epidemiology of non-Hodgkin's lymphoma","volume":"23","author":"Fisher","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0010","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The non-Hodgkin's lymphoma classification project","volume":"89","author":"Clinical evaluation of the International Lymphoma Study Group classification of non Hodgkin's lymphoma","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0015","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0025","series-title":"Non-Hodgkin's lymphomas","first-page":"711","article-title":"Overview of the etiology and epidemiology of lymphoma","author":"Hartge","year":"2004"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib0030","first-page":"300","article-title":"Lymphoid malignancies in Nebraska: a hypothesis","volume":"70","author":"Weisenburger","year":"1985","journal-title":"The Nebraska Medical Journal"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0035","first-page":"231","article-title":"The malignant lymphomas: epidemiology and related aspects","volume":"7","author":"Vianna","year":"1977","journal-title":"Pathobiology Annual"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0040","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2009.24.4194","article-title":"Epstein\u2013Barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia","volume":"28","author":"Sohani","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00000478-200205000-00009","article-title":"Epstein\u2013Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms","volume":"26","author":"Abruzzo","year":"2002","journal-title":"American Journal of Surgical Pathology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0050","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJM200312253492622","article-title":"An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab","volume":"349","author":"Ghobrial","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/00365540701684817","article-title":"Fatal adenoviral and enteroviral infections and an Epstein\u2013Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sezary syndrome","volume":"40","author":"Roch","year":"2008","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0060","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V90.2.776","article-title":"Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection","volume":"90","author":"De Vita","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0065","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ajcp\/109.5.600","article-title":"Extranodal lymphomas associated with hepatitis C virus infection","volume":"109","author":"Ascoli","year":"1998","journal-title":"American Journal of Clinical Pathology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1008255830453","article-title":"Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia","volume":"9","author":"Luppi","year":"1998","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0075","first-page":"471","article-title":"Hepatitis C viral genome in a subset of primary hepatic lymphomas","volume":"11","author":"Ohsawa","year":"1998","journal-title":"Modern Pathology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0080","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"340","article-title":"Lymphomas associated with HIV infection","author":"Raphael","year":"2008"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0085","series-title":"The lymphid neoplasms","first-page":"393","article-title":"Immunodeficiency, inherited and acquired, and lymphomagenesis","author":"Rossi","year":"2010"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0090","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"243","article-title":"EBV positive diffuse large B-cell lymphoma of the elderly","author":"Nakamura","year":"2008"},{"issue":"17","key":"10.1016\/j.critrevonc.2012.12.009_bib0095","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"American Journal of Surgical Pathology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0105","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/PAS.0b013e3182190999","article-title":"EBV-positive extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in the posttransplant setting: a distinct type of posttransplant lymphoproliferative disorder?","volume":"35","author":"Gibson","year":"2009","journal-title":"American Journal of Surgical Pathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.humpath.2009.07.024","article-title":"Epstein\u2013Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations","volume":"41","author":"Hoeller","year":"2010","journal-title":"Human Pathology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0115","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"258","article-title":"Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease","author":"Isaacson","year":"2008"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0120","series-title":"The lymphid neoplasms","first-page":"416","article-title":"Chronic inflammation, including autoimmunity, and lymphomagenesis","author":"Pileri","year":"2010"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05311.x","article-title":"The aetiology and management of Castleman disease at 50year: translating pathophysiology to patient care","volume":"129","author":"Casper","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0130","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"233","article-title":"Diffuse Large B-cell Lymphoma, not otherwise specified","author":"Stein","year":"2008"},{"issue":"23","key":"10.1016\/j.critrevonc.2012.12.009_bib0135","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1016\/j.critrevonc.2012.12.009_bib0145","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2002-04-1286","article-title":"Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma","volume":"101","author":"Colomo","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0165","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","article-title":"Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma","volume":"92","author":"Kramer","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0170","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V90.1.244","article-title":"Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma","volume":"90","author":"Gascoyne","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib0175","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"The Journal of Experimental Medicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2012.12.009_bib0180","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma","volume":"331","author":"Offit","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng0697-161","article-title":"The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation","volume":"16","author":"Ye","year":"1997","journal-title":"Nature Genetics"},{"issue":"5134","key":"10.1016\/j.critrevonc.2012.12.009_bib0195","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1126\/science.8235596","article-title":"Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma","volume":"262","author":"Ye","year":"1993","journal-title":"Science (New York, NY)"},{"issue":"24","key":"10.1016\/j.critrevonc.2012.12.009_bib0200","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1002\/j.1460-2075.1995.tb00311.x","article-title":"Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma","volume":"14","author":"Ye","year":"1995","journal-title":"EMBO Journal"},{"issue":"7017","key":"10.1016\/j.critrevonc.2012.12.009_bib0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nature03147","article-title":"The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells","volume":"432","author":"Phan","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/(SICI)1098-2264(199605)16:1<21::AID-GCC3>3.0.CO;2-5","article-title":"Molecular heterogeneity of B-lineage diffuse large cell lymphoma","volume":"16","author":"Volpe","year":"1996","journal-title":"Genes, Chromosomes and Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2012.12.009_bib0215","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJM198904203201605","article-title":"bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma","volume":"320","author":"Yunis","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/j.critrevonc.2012.12.009_bib0220","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0225","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF02983534","article-title":"Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma","volume":"79","author":"Ueda","year":"2004","journal-title":"International Journal of Hematology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0230","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"265","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","author":"Kluin","year":"2008"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0235","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1073\/pnas.94.11.5728","article-title":"BCL8, a novel gene involved in translocations affecting band 15q11\u201313 in diffuse large-cell lymphoma","volume":"94","author":"Dyomin","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7337","key":"10.1016\/j.critrevonc.2012.12.009_bib0240","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0245","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/ng1018","article-title":"Acetylation inactivates the transcriptional repressor BCL6","volume":"32","author":"Bereshchenko","year":"2002","journal-title":"Nature Genetics"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0250","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0092-8674(00)80521-8","article-title":"Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain","volume":"90","author":"Gu","year":"1997","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","article-title":"Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults","volume":"118","author":"Salaverria","year":"2011","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.critrevonc.2012.12.009_bib0260","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.critrevonc.2012.12.009_bib0265","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1016\/j.critrevonc.2012.12.009_bib0270","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"28","key":"10.1016\/j.critrevonc.2012.12.009_bib0275","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0280","first-page":"722","article-title":"Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study","volume":"9","author":"Linderoth","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0285","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0002-9440(10)63150-1","article-title":"Building an outcome predictor model for diffuse large B-cell lymphoma","volume":"164","author":"Saez","year":"2004","journal-title":"American Journal of Pathology"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.12.009_bib0290","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2005-04-1603","article-title":"Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL","volume":"106","author":"Moskowitz","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0295","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/00000478-200404000-00005","article-title":"Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma","volume":"28","author":"Chang","year":"2004","journal-title":"American Journal of Surgical Pathology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0300","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"238","article-title":"T cell\/histiocyte-rich large B-cell lymphoma","author":"De Wolf Peeters","year":"2008"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0305","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2008.07.020","article-title":"Primary mediastinal large B-cell lymphoma","volume":"68","author":"Martelli","year":"2008","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0310","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"250","article-title":"Primary mediastinal, (thymic) large B-cell lymphoma","author":"Gaulard","year":"2008"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdj030","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience","volume":"17","author":"Savage","year":"2006","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib0320","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0325","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Annals of Oncology"},{"issue":"21","key":"10.1016\/j.critrevonc.2012.12.009_bib0330","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0335","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"242","article-title":"Primary cutaneous DLBCL, leg type","author":"Meijer","year":"2008"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0340","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","article-title":"How I treat primary CNS lymphoma","volume":"118","author":"Ferreri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0345","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"240","article-title":"Primary diffuse large B-cell lymphoma of the central nervous system","author":"Kluin","year":"2008"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0350","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-05-2617","article-title":"Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma","volume":"12","author":"Booman","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0355","first-page":"1063","article-title":"BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma","volume":"9","author":"Braaten","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0360","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Broet","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0365","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/1078-0432.CCR-05-1699","article-title":"Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin","volume":"12","author":"Lin","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0370","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1750-3639.1998.tb00152.x","article-title":"Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL","volume":"8","author":"Cobbers","year":"1998","journal-title":"Brain Pathology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0375","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"247","article-title":"Lymphomatoid granulomatosis","author":"Pittaluga","year":"2008"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0380","series-title":"Tumours of haematopoietic and lymphoid tissue","author":"Jaffe","year":"2001"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0385","first-page":"660","article-title":"Review of lymphomatoid granulomatosis treated with rituximab and chemotherapy","volume":"1","author":"Hagberg","year":"2003","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0390","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"254","article-title":"ALK-positive large B-cell lymphoma","author":"Delsol","year":"2008"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0395","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"256","article-title":"Plasmablastic lymphoma","author":"Stein","year":"2008"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0400","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"260","article-title":"Primary effusion lymphoma","author":"Said","year":"2008"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0405","first-page":"1044","article-title":"Epstein\u2013Barr virus in pyothorax-associated pleural lymphoma","volume":"143","author":"Fukayama","year":"1993","journal-title":"American Journal of Pathology"},{"issue":"20","key":"10.1016\/j.critrevonc.2012.12.009_bib0410","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1200\/JCO.2002.09.021","article-title":"Pyothorax-associated lymphoma: a review of 106 cases","volume":"20","author":"Nakatsuka","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0415","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1023\/A:1008285708096","article-title":"Pyothorax-associated lymphoma: description of the first two cases detected in Italy","volume":"8","author":"Ascani","year":"1997","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0420","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/labinvest.3700235","article-title":"Alterations of DNA damage-response genes ATM and ATR in pyothorax-associated lymphoma","volume":"85","author":"Liu","year":"2005","journal-title":"Laboratory Investigation"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0425","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/01.pas.0000157747.10967.f4","article-title":"Metallic implant-associated lymphoma: a distinct subgroup of large B-cell lymphoma related to pyothorax-associated lymphoma?","volume":"29","author":"Cheuk","year":"2005","journal-title":"American Journal of Surgical Pathology"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0430","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF02982649","article-title":"Non-Hodgkin's lymphoma developing in a pacemaker pocket","volume":"77","author":"Hojo","year":"2003","journal-title":"International Journal of Hematology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0435","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","first-page":"267","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma","author":"Jaffe","year":"2008"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0440","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/028418519203300508","article-title":"Ultrasound guided tumour biopsy in the anterior mediastinum. An alternative to thoracotomy and mediastinoscopy","volume":"33","author":"Andersson","year":"1992","journal-title":"Acta Radiologica"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0445","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1996.14.9.2427","article-title":"Role of image-guided core-needle biopsy in the management of patients with lymphoma","volume":"14","author":"Pappa","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0450","first-page":"1860","article-title":"Report of the committee on Hodgkin lymphoma staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0455","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.critrevonc.2012.12.009_bib0460","first-page":"987","article-title":"The international non-Hodgkin's lymphoma prognostic factors project","volume":"329","author":"A predictive model for aggressive non-Hodgkin's lymphoma","year":"1993","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.12.009_bib0465","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0470","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1200\/JCO.2008.20.1665","article-title":"The case against heavy PETing","volume":"27","author":"Cheson","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0475","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0480","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2007.04.012","article-title":"Primary central nervous system lymphoma","volume":"63","author":"Ferreri","year":"2007","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2003.11.141","article-title":"Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group","volume":"21","author":"Zucca","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0490","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.critrevonc.2007.01.003","article-title":"Primary diffuse large B-cell lymphoma of the stomach","volume":"63","author":"Ferreri","year":"2007","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0495","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"May (14)","key":"10.1016\/j.critrevonc.2012.12.009_bib0500","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1016\/j.critrevonc.2012.12.009_bib0505","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"6769","key":"10.1016\/j.critrevonc.2012.12.009_bib0510","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0515","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0520","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.critrevonc.2012.12.009_bib0525","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2012.12.009_bib0530","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0535","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.critrevonc.2012.12.009_bib0540","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib0545","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2012.12.009_bib0550","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0555","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0560","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0565","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/annonc\/mdm514","article-title":"Dose-escalated CHOEP, for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"19","author":"Pfreundschuh","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0570","first-page":"169","article-title":"R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B cell lymphoma: results of the interim analysis of the LNH03-6B GELA study","volume":"114","author":"Delarue","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0575","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8000","article-title":"CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma","volume":"29","author":"Cunningham","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0580","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"Imrie KCHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0585","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"Gill DSCHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0590","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008394827806","volume":"11","author":"Haioun","year":"2000","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1016\/j.critrevonc.2012.12.009_bib0595","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1016\/j.critrevonc.2012.12.009_bib0600","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2012.12.009_bib0605","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial","volume":"21","author":"Martelli","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0610","first-page":"793","article-title":"High dose sequential chemotherapy with autologous transplantation versus dose-dense hemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an \u201cIntergruppo Italiano Linfomi\u201d randomized trial","volume":"90","author":"Vitolo","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0615","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ctrv.2007.02.002","article-title":"High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma \u2013 results of a comprehensive meta-analysis","volume":"33","author":"Greb","year":"2007","journal-title":"Cancer Treatment Reviews"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0620","first-page":"1304","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis","volume":"88","author":"Strehl","year":"2003","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0625","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0630","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib0635","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1570","article-title":"Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma","volume":"107","author":"Glass","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0640","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2009.007005","article-title":"Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study","volume":"94","author":"Vitolo","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0645","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2008.07383.x","article-title":"Use of rituximab in diffuse large B-cell lymphoma in the salvage setting","volume":"143","author":"Gisselbrecht","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib0650","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0655","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2011-01-329268","article-title":"IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression","volume":"118","author":"Milpied","year":"2011","journal-title":"Blood"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2012.12.009_bib0660","volume":"29","author":"Stiff","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl. 4","key":"10.1016\/j.critrevonc.2012.12.009_bib0665","volume":"22","author":"Vitolo","year":"2011","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1016\/j.critrevonc.2012.12.009_bib0670","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdf175","article-title":"Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model","volume":"13","author":"Hollender","year":"2002","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0675","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","volume":"91","author":"van Besien","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0680","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1008260120532","article-title":"For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group","volume":"9","author":"Bos","year":"1998","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0685","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/asheducation-2002.1.283","article-title":"Central nervous system lymphoma","author":"Lister","year":"2002","journal-title":"American Society of Hematology Education Program"},{"issue":"17","key":"10.1016\/j.critrevonc.2012.12.009_bib0690","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0695","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0700","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.critrevonc.2010.12.003","article-title":"Lymphoblastic lymphoma","volume":"79","author":"Cortelazzo","year":"2011","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"18","key":"10.1016\/j.critrevonc.2012.12.009_bib0705","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0710","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1016\/j.critrevonc.2012.12.009_bib0715","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0720","first-page":"613","article-title":"Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma","volume":"85","author":"Jerusalem","year":"2000","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0725","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0730","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0735","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"Journal of Nuclear Medicine"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0740","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy","volume":"50","author":"Itti","year":"2009","journal-title":"Journal of Nuclear Medicine"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0745","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib0750","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2012.12.009_bib0755","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"Bonnet","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0760","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0765","first-page":"724a","article-title":"CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial","volume":"98","author":"Miller","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0770","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib0775","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/10428190410001723269","article-title":"Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma","volume":"45","author":"Avil\u00e9s","year":"2004","journal-title":"Leukemia and Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0780","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000012104","article-title":"Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III\u2013IV diffuse large B cell lymphomas","volume":"58","author":"Ferreri","year":"2000","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0785","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2006.05.006","article-title":"Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma","volume":"66","author":"Moser","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0790","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0360-3016(00)00760-4","article-title":"Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III\u2013IV, intermediate grade and large-cell immunoblastic lymphomas","volume":"48","author":"Schlembach","year":"2000","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"27","key":"10.1016\/j.critrevonc.2012.12.009_bib0795","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2009.27.3441","article-title":"Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy","volume":"28","author":"Phan","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2012.12.009_bib0800","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.20.1.197","article-title":"Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency","volume":"20","author":"Shenkier","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1016\/j.critrevonc.2012.12.009_bib0805","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1016\/j.critrevonc.2012.12.009_bib0810","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0815","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V75.4.831.831","article-title":"The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation","volume":"75","author":"Phillips","year":"1990","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0820","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/JCO.1990.8.4.638","article-title":"Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle","volume":"8","author":"Petersen","year":"1990","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0825","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1200\/JCO.2002.09.138","article-title":"Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease","volume":"20","author":"Vose","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.12.009_bib0830","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1200\/JCO.1992.10.10.1615","article-title":"Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen","volume":"10","author":"Bosly","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.12.009_bib0835","first-page":"3562","article-title":"The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.12.009_bib0840","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","article-title":"Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial","volume":"16","author":"Guglielmi","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.critrevonc.2012.12.009_bib0845","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0850","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"et Rituximab improves the treatment results of DHAP\u2013VIM\u2013DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.critrevonc.2012.12.009_bib0855","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2012.12.009_bib0860","article-title":"Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis","volume":"29","author":"Gisselbrecht","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0865","series-title":"Relapsed\/refractory diffuse large B-cell lymphoma (DLBCL): the bio-CORAL study blood (ASH)","article-title":"Prognostic impact of germinal center (GC)\/activated B-cell (ABC) classification analysed by immunochemistry, FISH analysis and GEP","author":"Thieblemont","year":"2010"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0870","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0875","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.22911","article-title":"The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation","volume":"110","author":"Filmont","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0880","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/10428190601158639","article-title":"Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation","volume":"48","author":"Vose","year":"2007","journal-title":"Leukemia and Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0885","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","article-title":"Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma","volume":"35","author":"Shimoni","year":"2007","journal-title":"Experimental Hematology"},{"issue":"4","key":"10.1016\/j.critrevonc.2012.12.009_bib0890","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1705919","article-title":"Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma","volume":"41","author":"Shimoni","year":"2008","journal-title":"Bone Marrow Transplantation"},{"issue":"19","key":"10.1016\/j.critrevonc.2012.12.009_bib0895","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib0900","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT, registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplantation"},{"issue":"13","key":"10.1016\/j.critrevonc.2012.12.009_bib0905","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0910","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood.V108.11.602.602","article-title":"Matched unrelated donor stem cell transplantation for patients with diffuse large B cell lymphoma: A retrospective analysis of 118 patients registered through the European Group for Blood and Marrow Transplantation (EBMT)","volume":"108","author":"Avivi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0915","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","article-title":"Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan","volume":"36","author":"Kusumi","year":"2005","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0920","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory Non-Hodgkin's Lymphoma (NHL)","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib0925","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib0930","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2012.12.009_bib0935","article-title":"Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large-B-cell lymphoma: results of an international study (NHL-003)","volume":"112","author":"Czuczman","year":"2008","journal-title":"Blood (ASH)"},{"issue":"30","key":"10.1016\/j.critrevonc.2012.12.009_bib0940","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0945","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nature Reviews Immunology"},{"issue":"5","key":"10.1016\/j.critrevonc.2012.12.009_bib0950","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/auto.6232","article-title":"Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers","volume":"4","author":"Younes","year":"2008","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0955","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.critrevonc.2012.12.009_bib0960","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2012.12.009_bib0965","article-title":"Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): preliminary analysis","volume":"29","author":"Hainsworth","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2012.12.009_bib0970","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib0975","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3109\/10428194.2012.656629","article-title":"Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma","volume":"53","author":"Elstrom","year":"2012","journal-title":"Leukemia and Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib0980","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1517\/14712598.2010.498418","article-title":"Inotuzumab ozogamicin as novel therapy in lymphomas","volume":"10","author":"Wong","year":"2010","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"17","key":"10.1016\/j.critrevonc.2012.12.009_bib0985","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2012.12.009_bib0990","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Experimental Cell Research"},{"issue":"2","key":"10.1016\/j.critrevonc.2012.12.009_bib0995","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4132\/KoreanJPathol.2012.46.2.142","article-title":"Expression of HAT1 and HDAC1\u20133 in diffuse large B-cell lymphomas, peripheral T-cell lymphomas, and NK\/T-cell lymphomas","volume":"46","author":"Min","year":"2012","journal-title":"Korean Journal of Pathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2012.12.009_bib1000","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1705414","article-title":"A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60years with untreated poor-prognosis diffuse large B-cell lymphoma","volume":"38","author":"Coso","year":"2006","journal-title":"Bone Marrow Transplantation"},{"issue":"7","key":"10.1016\/j.critrevonc.2012.12.009_bib1005","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428190500525656","article-title":"Rituximab-CHOP-ESHAP vs. CHOP-ESHAP-high-dose therapy vs. conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma","volume":"47","author":"Intragumtornchai","year":"2006","journal-title":"Leukemia and Lymphoma"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib1010","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1182\/blood-2005-12-4898","article-title":"Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"107","author":"Stewart","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2012.12.009_bib1015","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/sj.leu.2404781","volume":"21","author":"Tarella","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2012.12.009_bib1020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V110.11.21.21","article-title":"Treatment of diffuse large B-cell lymphoma with rituximab, intensive induction and high-dose consolidation: the final analysis of the Czech lymphoma study group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) trial","volume":"110","author":"Trneny","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2012.12.009_bib1025","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma","volume":"20","author":"Haioun","year":"2009","journal-title":"Annals of Oncology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T09:13:41Z","timestamp":1595322821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":205,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1040842813000024"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}